Economic Assessment of the Secondary Prevention of Ischaemic Events with Lysine Acetylsalicylate

Abstract

Our results underline the high economic benefit of using lysine acetylsalicylate to prevent secondary ischaemic stroke and MI in patients at high risk of cardiovascular and/or cerebrovascular events, leading to savings for the social security system and society.

Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial

“…Aspirin is a widely used and cheap antithrombotic agent for the prevention of secondary vascular events 20 , and the economic advantages of the secondary treatment of patients with a history of MI and IS with aspirin compared to placebo from a French perspective has been reported by Marissal et al 21 . However, to date there have been several reports of other antithrombotic treatment regimens that are cost-effective compared to aspirin alone 22,23 .…”

Cost of stroke in France

“… estimated the 5‐year cost of caring for incident strokes at €4156 billion in stroke units and €3718 billion in conventional units. The 1‐year cost for the healthcare system was estimated at €17 800 per patient in 2000 . The 1998 burden of cerebrovascular diseases in France was estimated at €2.2 billion (2007€) using a top‐down approach to attribute a portion of national healthcare expenditures to cerebrovascular diseases .…”

Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care

“…In the United Kingdom a variety of secondary prevention methods are recommended by the National Institute for Health and Clinical Effectiveness (NICE) 6. There is also evidence to suggest that many forms of secondary prevention may be cost-effective; examples include angiotensin-converting enzyme (ACE) inhibitors,7 – 10 β-blockers after myocardial infarction,11 12 statins for the secondary prevention of coronary heart disease13 14 and the use of aspirin 15…”